Octreotide and diabetes: theoretical and experimental aspects.
Diabetes is characterized by paradoxical hypersomatotropinemia and hyperglucagonemia. The latter appears to enhance the tendency in imperfect metabolic control to reduce nitrogen balance, and the former appears to accelerate the deterioration of carbohydrate and lipid metabolism, and also to induce peripheral insulin resistance and hyperinsulinemia. In addition to direct metabolic effects, increasing evidence points to an association between hypersomatotropinemia and a number of metabolically dependent, characteristic functional abnormalities linked to the development of late diabetic manifestations. These include increased capillary fragility, lipid and hemostatic aberrations, tissue hyperperfusion, including increased cardiac output and renal plasma flow, and kidney hypertrophy. In theory, octreotide's actions could reduce these aberrations, and, in fact, this has been confirmed in recent experimental trials.
Orskov
H
H
Institute of Experimental Clinical Research, Aarhus Kommunehospital, Denmark.
Flyvbjerg
A
A
Frystyk
J
J
Ledet
T
T
Møller
N
N
Christensen
S E
SE
Harris
A G
AG
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005934:Glucagon / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015282:Octreotide / Q000494:pharmacology / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000378:metabolism
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D005934:Glucagon; D015282:Octreotide